The charts on this page feature a breakdown of the total annual pay for the top executives at MOMENTA PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. MOMENTA PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. MOMENTA PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Craig A. Wheeler
President, Chief Executive Officer and Director
Total Cash $1,380,000 Equity $3,200,191 Other $30,079 Total Compensation $4,610,270
Scott M. Storer
Former Senior Vice President and Chief Financial Officer
Total Cash $420,877 Equity $896,500 Other $667,588 Total Compensation $1,984,965
Michelle Robertson
Chief Financial Officer
Total Cash $448,395 Equity $747,662 Other $13,516 Total Compensation $1,209,573
Young Kwon
Chief Business Officer
Total Cash $614,196 Equity $1,742,100 Other $13,378 Total Compensation $2,369,674
Anthony Manning
Chief Scientific Officer
Total Cash $509,842 Equity $1,660,600 Other $13,709 Total Compensation $2,184,151
Santiago Arroyo
Senior Vice President Development and Chief Medical Officer
Total Cash $631,346 Equity $1,660,600 Other $13,480 Total Compensation $2,305,426
For its 2018 fiscal year, MOMENTA PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Craig A. Wheeler CEO Pay $4,632,770 Median Employee Pay $175,536 CEO Pay Ratio 26:1
For its 2018 fiscal year, MOMENTA PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Bruce L. Downey Total Cash $284,103
Corey N. Fishman Total Cash $271,103
Elizabeth Stoner Total Cash $268,603
Georges Gemayel Total Cash $268,603
James R. Sulat Total Cash $278,603
Jose-Carlos Gutiérrez-Ramos Total Cash $266,603
Steven C. Gilman Total Cash $266,603
Thomas P. Koestler Total Cash $269,103

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.